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a-Melanocyte-stimulating hormone is produced by
several different cell types including neural cells, endo-
thelial cells, monocytes, and keratinocytes. A biologic
role in melanocyte pigmentation is widely recognized,
but more recent studies describe a part in modulating
inflammatory and immune responses. The aim of the
this study was to investigate the mechanism by which
a-melanocyte-stimulating hormone antagonizes pro-
inflammatory cytokine action. We report that
a-melanocyte-stimulating hormone (10–9 M) was
effective in opposing a tumor necrosis factor-a stimu-
lated increase in NF-kB DNA binding activity in:
(i) normal ocular melanocytes; (ii) cells cultured from
ocular melanoma tumors; and (iii) two cutaneous
melanoma cell lines. NF-kB is activated by many
inflammatory mediators and controls transcription of
genes required for immune and inflammatory
responses. The transcription factor complex was posit-
ively identified as the p50/p65 heterodimer, recognized
to have transcriptional activating potential. Maximum
α -Melanocyte-stimulating hormone (α-MSH) is anevolutionary conserved 13 amino acid peptide,which arises by proteolytic processing of pro-opiomelanocortin. It is produced in several ver-tebrate tissues including the pituitary, brain, and
skin (Eberle, 1988; Catania and Lipton, 1993; Lipton and Catania,
1997). Although initially named for having a pigmentary role, a
number of studies now report that α-MSH has a potent effect in
modulating host reactions such as fever, inflammation, and immune
system regulation (Lipton et al, 1991; Martin et al, 1991; Weiss
et al, 1991; Watanabe et al, 1993; Bhardwaj and Luger, 1994; Lipton
and Catania, 1997). Several lines of evidence suggest that it exerts
these properties through the central nervous system or peripherally
located melanocortin receptors (MC1R). The mechanism by which
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reduction of NF-kB DNA binding activity with
a-melanocyte-stimulating hormone was detected 2 h
after cellular stimulation and varied from between
53% and 18% depending on cell type. Whereas the
acute inhibitory effects could be mimicked by elevating
cyclic adenosine monophosphate, a-melanocyte-
stimulating hormone was not found to have any effect
on the relative level of IkBa protein expression over
24 h. These data show that a-melanocyte-stimulating
hormone has a pronounced effect on NF-kB activity
in melanocytes and melanoma cells, identifying a
specific dimeric complex, and suggest this to be a key
pathway by which immunomodulation/anti-inflam-
mation may operate. The results may also be consid-
ered in the broader context of general inflammatory
pathologies concerning cells which express a-melano-
cyte-stimulating hormone receptors and utilize the
NF-kB signaling pathway. Key words: cancer/immunomo-
dulation/inflammation/pigmentation/transcription factors. J
Invest Dermatol 113:560–566, 1999
anti-pyretic, anti-inflammatory, and immunomodulatory activities
arise is not completely understood, but an inhibition of production
or action of proinflammatory cytokines [e.g., interleukin (IL)-1
(Weiss et al, 1991)] and the increased synthesis of anti-inflammatory
cytokines (e.g., IL-10; Bhardwaj et al, 1996) are considered central
to these roles.
Previous work from our group supports a role for α-MSH in
cutaneous immunomodulation, by showing that α-MSH opposes
the action of a proinflammatory cytokine [tumor necrosis factor
(TNF) -α], which normally upregulates intercellular adhesion
molecule-1 (ICAM-1) expression on melanocytes and melanoma
cells (Hedley et al, 1998; Morandini et al, 1998). Surface ICAM-1
expression is an obligatory requirement (but not a sole prerequisite)
for T lymphocyte binding to cells, necessary for local inflammation.
It is also known that melanoma cells produce immunoreactive
α-MSH (Ghanem et al, 1989; Lunec et al, 1990; Loir et al, 1997).
Therefore, α-MSH may have an immunomodulatory role which
could prevent immune system recognition of these cells (via an
autocrine and/or paracrine mechanism) facilitating transformation
or metastatic spread of melanoma. A similar mechanism may
prevent the melanocyte becoming a premature target for the
immune system during episodes of ultraviolet inflammation and
associated damage (Morandini et al, 1998; Hedley et al, 1998).
The signaling pathway by which α-MSH may oppose pro-
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inflammatory cytokine action is not fully understood. It has been
shown recently, however, that α-MSH can block NF-κB activation
in inflammatory cells in vitro (Manna and Aggarwal, 1998). It is
also known that many cytokines act by rapidly inducing Rel/NF-
κB activity. This family of transcription factors is present in many
cell types in addition to those of immune origin (Baeuerle and
Henkel, 1994). NF-κB is the most commonly studied form and is
composed of p50 and p65 (Ghosh et al, 1990; Ruben et al, 1991).
Many genes contain κB-binding consensus motifs, including acute
phase response proteins, cytokines, and adhesion molecules
(Baeuerle and Henkel, 1994). Therefore, NF-κB has a key role in
inflammation, cellular migration, repair, and the activation of
immune cells. As we have previously shown TNF-α to block
upregulation of ICAM-1 protein and mRNA synthesis in melano-
cytes (Hedley et al, 1998) and melanoma cells (Morandini et al,
1998) and as this gene is largely under NF-κB-dependent control
(Muller et al, 1995), we investigated the ability of α-MSH to
prevent activation of Rel/NF-κB proteins in melanocytes and
melanoma cells.
MATERIALS AND METHODS
Human melanoma cell line culture A-375SM and HBL are human
cutaneous melanoma cell lines. The A-375SM cell line was a generous gift
from I.J. Fidler (U.S.A.) via M.J.Humphries (University of Manchester,
U.K.). Cells were cultured in Eagles minimum essential medium (Gibco
Life, Ichannan, U.K.) supplemented with 10% fetal bovine serum (Globe
Pharmaceuticals, Esher, U.K.), 2 mM L-glutamine (Sigma, Poole, U.K.),
1% nonessential amino acids (Sigma), 0.187% sodium hydrogen carbonate
(Sigma), 1 mM sodium pyruvate (Sigma), 1.5% vitamin concentrate
(Sigma), 100 µg streptomycin per ml (Sigma), 1.2 µg Fungizone per ml
(Sigma), and 100 units penicillin per ml (Sigma). HBL is a melanoma cell
line established in one of our laboratories (GG) (Ghanem et al, 1988). Cells
were cultured in Ham F-10 (Gibco) supplemented with 5% fetal bovine
serum, 5% NCS (APP, West Midlands, U.K.), 2 mM L-glutamine, 100 units
penicillin per ml and 100 µg streptomycin sulfate per ml.
Human uveal melanoma tumor cell culture Tumor samples were
obtained from freshly enucleated eyes which had been surgically removed
due to the presence of large posterior uveal melanoma. Cells were cultured
as previously described (Goodall et al, 1994) in Ham’s F12:Dulbecco’s
minimal essential medium (1:1 vol/vol; Sigma) supplemented with 10%
fetal bovine serum, 10 µg insulin per ml, 10 µg transferrin per ml, 100 units
penicillin per ml, 100 µg streptomycin sulfate per ml, 2 mM L-glutamine,
and 0.187% sodium hydrogen carbonate, pH 7.4. All experiments were
conducted within six passages of the primary cultured cells.
Human uveal melanocyte culture Melanocytes were cultured as
described previously (Goodall et al, 1994) in MCDB153 (Sigma) supple-
mented with 2% chelexed fetal bovine serum, 10 µg transferrin per ml,
10 µg insulin per ml, 2 mM glutamine, 100 units penicillin per ml, 100 µg
streptomycin sulfate per ml, 2.8 µg hydrocortisone per ml, 10 units nystatin
per ml, 1 µg vitamin E per ml (Sigma), 100 ng cholera toxin per ml
(Sigma), 10 nM phorbol 12-myristate 13-acetate (Sigma), 0.6 ng basic
fibroblast growth factor per ml (Sigma), and 50 µg bovine pituitary extract
per ml (Gibco, Paisley, U.K.). Cells were fed every 3–4 d and passaged
when near confluent. Ten days before experimentation cells were fed with
a basal medium supplemented only with insulin, transferrin, hydrocortisone,
and basic fibroblast growth factor (omitting cholera toxin). All experiments
were conducted within six passages of the primary cultures.
Experimental procedure Melanoma cells were seeded in to T75 flasks
at 2 3 106 cells and melanocytes at 1 3 106 cells per T25 flask and grown
to approximately 60% confluence. Media was changed 18 h prior to
experimentation and cell effectors added for 30 min, 1, 2, or 3 h [α-MSH,
1 3 10–11 M to 1 3 10–6 M; 200 units TNF-α per ml; iso-butyl
methylxanthine (IBMX), 1 mM]. α-MSH or IBMX were added to the
cells 15 min prior to additions of TNF-α. Incubations were terminated by
medium removal and washing (3 2) of cells in phosphate-buffered saline.
Cells were then processed for nuclear extraction.
Nuclear extracts and electrophoretic mobility shift assay Cells were
harvested using a cell scraper into 10 mM HEPES buffer (pH 7.9)
containing 1.5 mM MgCl2, 10 mM KCl, and 0.1% Nonidet p-40. Nuclear
extracts were prepared as described previously (Dignam et al 1983). Samples
were centrifuged (12,000 3 g, 5 min) and the pellet suspended in 20 mM
HEPES buffer, pH 7.9 containing 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM
ethylenediamine tetraacetic acid, 25% glycerol, incubated on ice (10 min)
and centrifuged (12,000 3 g, 5 min). Supernatant was diluted in 20 mM
HEPES buffer, with 0.05 M KCl, 0.2 mM ethylenediamine tetraacetic
acid, 20% glycerol, and centrifuged (12000 3 g, 5 min). Supernatant from
the latter centrifugation (containing the nuclear fraction) was measured for
protein content using the BCA technique (Pierce, Rochford, IL). Five
micrograms of protein from each sample were mixed with a reaction buffer
(1 mM ethylenediamine tetraacetic acid, 50 mM NaCl, 10 mM Tris)
containing 50 µg poly(dI-dC) per ml (Promega, Southampton, U.K.) and
end-labeled oligonucleotide probe. The NF-κB probe was a 25-mer
double-stranded synthetic oligonucleotide (VH Bio, Gosforth, U.K.) con-
taining the κB motif (59-TGACAGAGGGGACTTCCGAGAGGA-39).
End-labeling was by T4 polynucleotide kinase (Promega) reaction with
[γ-32P]ATP (NEN, Brussels, Belgium). Samples were loaded on to a 4%
polyacrylamide gel (38:1) in 1 3 tris-borate EDTA (pre-run for 30 min)
and run at 100 V for 1 h, at 4°C. Gels were dried and exposed to film
(AmershamPharmacia hyperfilm, Amersham, U.K.) for 18 h at –70°C with
intensifying screens (Hypercassette, AmershamPharmacia). Quantitation of
NF-κB activity was by done by scanning densitometry of the p 50/p65
specific gel shift band (as a ratio of the excess unbound radiolabeled
oligonucleotide band, as internal control) using a GS-700 imaging densito-
meter in transmittance mode integrating optical density and cross-sectional
area, using ‘‘Molecular Analyst’’ software (600 d.p.i., BioRad, Hemel
Hempstead, U.K.).
Determination of NF-kB binding specificity and subunit
composition Cells were treated as described above, stimulated with or
without TNF-α (200 units per ml) for 60 min and then the nuclear
fraction extracted. An excess of cold native oligonucleotide (200 M) was
added in addition to radiolabeled oligonucleotide in the sample binding
reaction described above, prior to running samples as before. In addition,
an excess of cold mutant oligonucleotide was also used (containing a single
base pair mutation (G → C) of the native oligonucleotide probe: 59-
TGACAGAGGGCACTTCCGAGAGGA-39). For identification of sub-
unit composition, nuclear extracts were incubated with rabbit polyclonal
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) against the p65 or
p50 NF-κB subunits. The relative proportions in shifted and nonshifted
bands were determined for each condition by scanning densitometry.
Western immunoblotting analysis for IkB-a Cells were seeded into
six well plates at 105 per well and grown until 60% confluent. Medium
was changed 18 h prior to addition of α-MSH. Cells were incubated for
0, 2, 8, and 16 h using 10–9 M α-MSH, and also for 24 h using 10–10,
10–9, 10–8, and 10–7 M α-MSH. Total cellular protein was then extracted
for protein measurement (using BCA assay kit; Pierce) and the remainder
of the extract was incubated at 100°C for 2 min in a 75 mM Tris–HCl
buffer pH 6.8 (containing 15% sodium dodecyl sulfate, 5%
β-mercaptoethanol, 20% glycerol, 0.001% bromophenol blue). Ten micro-
grams of total protein was loaded per gel track and samples electrophoresed
according to the method of Laemlli (1970) (Mini Protean II dual slab cell,
BioRad) using a 10% stacking gel and 11% resolving gel for 1 h (200 V,
constant voltage). Proteins were transferred on to 0.45 µm nitrocellulose
membrane (BioRad) (according to the method of Towbin et al (1979)
(using a Mini Trans-Blot system, BioRad; 100 V, constant voltage). IκB-α
immunoreactive band was visualized as follows: unreacted binding sites
were blocked with 5% (wt/vol) commercial dried milk powder in TBST
[10 mM Tris–HCl, 0.15 M NaCl, 0.05% (wt/vol) Tween 20, pH 8.0],
followed by incubation with primary rabbit polyclonal IgG specific antibody
to IκB-α [(c-21) Santa Cruz Biotechnology (diluted 1:75 (vol/vol) with
TBST], washed with TBST (3 3 10 min) and incubated with horseradish
peroxidase-conjugated goat anti-rabbit secondary antibody diluted 1:2000
(vol/vol) in TBST (Dako, Cambridge, U.K.). Immunoreactive bands were
visualized using an Enhanced Chemiluminescence (ECL) kit (Amersham-
Pharmacia), with a precise exposure time of 2 min per Enhanced Chemi-
luminescence film sheet (AmershamPharmacia).
Statistics Student’s paired t test was used to analyze data where identical
cellular treatments were present as a continuous series differing by incubation
time only. Nonparametric Mann–Whitney analysis was used to analyze data
for identical incubation time-points, differing by sample treatment rationale.
RESULTS
Constitutive and inducible NF-κB activity was determined for
A375-SM and HBL cutaneous melanoma cell lines, human ocular
melanoma tumor cells, and human ocular melanocytes. No basal
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Figure 1. a-MSH inhibition of NF-kB activation and identification
of NF-kB complex composition. (a) Typical results showing A375-SM
cutaneous melanoma cells stimulated with TNF-α (200 U per ml) alone
or in combination with α-MSH (1 3 10–9 M) or untreated (Control) for
1 h. Nuclear extracts were incubated with labeled oligonucleotide probe
containing the NF-κB binding site. Autoradiograph obtained following
electrophoretic mobility shift assay (4% acrylamide) is shown. Arrow indicates
position of NF-κB p50/p65 specific band. (b, c) DNA binding complex
consists of p50/p65 heterodimer. A paired sample of HBL cutaneous
melanoma cells were unstimulated or stimulated with TNF-α (200 U per
ml, 60 min). Typical results show: (b, autoradiograph 1) lane 1, no
stimulation (negative control); lane 2, TNF-α (positive control, the same
sample was used for all subsequent analyses, (b, lanes 3 and 4 and c lanes
1–7); lanes 3 and 4, supershift analysis using anti-p50 antibody (1 µl and
2 µl); (c, autoradiograph 2) lanes 1 and 2, 100 M and 200 M excess non-
32P-radiolabeled native oligonucleotide; lanes 3 and 4, 100 M and 200 M
excess non-32P-radiolabeled mutant oligonucleotide; lanes 5 and 6,
supershift analysis using anti-p65 antibody (1 µl and 2 µl); lane 7, TNF-α
(positive control). Arrow, indicates position of NF-κB p50/p65 specific band.
NF-κB activity was observed for any of the above cell types. Acute
addition of the proinflammatory cytokine TNF-α (200 units per
ml), however, showed a marked increase in the DNA binding
activity of NF-κB after a 1 h incubation time period, as determined
by electrophoretic mobility shift assay. The complex was demon-
strated to be the p50/p65 heterodimer (Fig 1). Identical samples
stimulated with TNF-α (1 h), with 100 and 200 molar excess cold
oligonucleotide incorporated, showed specific competition for the
NF-κB:DNA complex (indicated by arrow), with a complete
reduction in radiolabeling intensity of binding product (Fig 1c,
lanes 1 and 2). Incorporation of 100 and 200 molar excess of mutant
oligonucleotide (containing a single G→C base pair mutation in
the signal motif recognition site) was demonstrated not to compete
for binding (Fig 1c, lanes 3 and 4). Antibody ‘‘supershift’’ analysis,
using polyclonal antisera specific for the p65 or p50 NF-κB
monomers, revealed specific displacements of the band from the
native position (relative migratory electrophoretic distance, Rf 5
0.23) to Rf 5 0.14 [Fig 1b, lanes 3 and 4 (anti-p50), and Fig 1c,
lanes 5 and 6 (anti-p65)], thereby confirming the composition of
the NF-κB complex as a p50/p65 heterodimer.
Typical results obtained by electrophoretic mobility shift assay
analysis demonstrating the potent inhibitory action of α-MSH on
NF-κB-binding activity are shown in Fig 1(a), where A375-SM
cells have been incubated for 1 h with TNF-α and α-MSH alone,
and in combination. Figure 2 shows combined data of several
such experiments (measured by scanning densitometry of the
specific band product under identical comparative conditions).
Addition of TNF-α alone (200 U per ml) to A375-SM cutaneous
melanoma cells increased NF-κB activity acutely with maximal
activity identified after 2 h incubation (Fig 2a, n 5 9). The relative
level of activity attained after 1 and 3 h was significantly less in
comparison [p 5 0.01, n 5 9 (1 h) and p 5 0.0001, n 5 3 (2 h)].
Maximal inhibition of NF-κB binding activity was observed at
1 3 10–9 M α-MSH for the A375-SM melanoma cell line (38%
of maximum, p 5 0.005, n 5 3) (Fig 2b). The most potent
concentration of the peptide was used for investigating α-MSH
inhibitory action for all subsequent cell types. For A375-SM cells,
coincubation of α-MSH (1 3 10–9 M) and TNF-α (200 U per
ml) decreased the level of NF-κB binding to 57% (p 5 0.03; n 5
9) after 1 h and to 28% (p 5 0.0005; n 5 7) after 2 h coincubation
(relative to the NF-κB-binding activity attained by TNF-α alone
for the same incubation time). After 3 h coincubation, 60% relative
binding activity was measured (n 5 3, not significant). A similar
inhibitory potential was also observed for cells coincubated with
IBMX (1 mM, a phosphodiesterase inhibitor) and TNF-α (200 units
per ml), with reductions in NF-κB binding activity to 67% (p 5
0.19, n 5 3), 54% (p 5 0.03, n 5 3), and 43% (p 5 0.04, n 5
3) after 1, 2, and 3 h, respectively. It was of note that incubating
cells with α-MSH (1 3 10–9 M; n 5 15) or IBMX (1 mM, n 5
4) alone did not affect the level of NF-κB activity.
Ocular melanoma tumor cells stimulated with TNF-α (200 U
per ml) alone activated NF-κB maximally after 2 h incubation
(Fig 2c, n 5 4), with 80% relative activity after 1 h (p 5 0.29,
n 5 4) and 43% after 3 h (p 5 0.02, n 5 3). Co-incubation of
TNF-α (200 U per ml) and α-MSH (1 3 10–9 M) for 1, 2, or
3 h decreased comparative binding activities to 63% (p 5 0.01,
n 5 4), 53% (p 5 0.02, n 5 4), and 87% (p 5 0.2, n 5 3),
respectively. Co-incubation with IBMX (1 mM) for 1, 2, or 3 h
reduced binding activities to 66% (p 5 0.16, n 5 3), 41% (p 5
0.05, n 5 3), and 71% (p 5 0.49, n 5 3). Incubation of cells with
α-MSH (1 3 10–9 M; n 5 15) or IBMX (1 mM; n 5 3) alone
did not affect NF-κB activity.
Ocular melanocytes stimulated with TNF-α (200 U per ml)
alone showed maximum NF-κB activation after 1 h incubation,
which was maintained after 2 h (Fig 2d; n 5 3). For the normal
cell type, however, relative activity observed after 1 h incubation
was not significantly different. A decrease in activity was observed
after 3 h to 42% relative activity (p 5 0.009, n 5 3), consistent
with the neoplastic cell types. Potent inhibition of NF-κB activity
occurred after 1 and 2 h coincubation with α-MSH (1 3 10–9 M)
and TNF-α (200 U per ml), with comparative activities of 54%
(p 5 0.05, n 5 3) and 53% (p 5 0.02, n 5 3), respectively. After
3 h, NF-κB activity was reduced to 67% (p 5 0.29, n 5 3). Co-
incubation with IBMX (1 mM) and TNF-α (200 U per ml) for
1, 2, or 3 h reduced binding activities to 32% (p 5 0.03, n 5 3),
25% (p 5 0.006, n 5 3), and 46% (p 5 0.29, n 5 3). As noted
above, incubation with α-MSH (1 3 10–9 M, n 5 8) or IBMX
(1 mM, n 5 6) alone did not affect NF-κB DNA binding activity.
The HBL cutaneous melanoma cell line responded to TNF-α
treatment with an acute increase in NF-κB activity after 30 min
which was 70% (p 5 0.17, n 5 3) of the maximum activity observed
after 1 h (Fig 2e). A reduction to 31% of relative maximum activity
was observed after 2 h (p 5 0.01, n 5 3). It was noted that after
3 h stimulation with TNF-α, no NF-κB activity was measured. A
significantly greater DNA binding inhibition was observed for this
cell type than for the former types described above when α-MSH
was present. After 30 min, 1 h and 2 h coincubation with α-MSH
(1 3 10–9 M) and TNF-α (200 units per ml) comparative activities
of 43% (p 5 0.03, n 5 3), 19% (p 5 0.0002; n 5 7), and 33% (p 5
0.09, n 5 3) were measured. This cell line is known to express a very
high level of MC-1 type surface receptors in comparison with other
cell types (Ghanem et al, 1988).
Western immunoblotting for I-κB, the NF-κB inhibitor subunit,
was performed on the A-375SM cutaneous melanoma and HBL
cutaneous melanoma cell lines. Two immunoreactive bands were
observed in whole untreated cell extracts with an electrophoretic
migration of 37 kDa (Fig 3). The immunoreactive products
migrated very closely together, with the lower of the two bands
having a greater immunoreactive intensity. (The faint upper band
VOL. 113, NO. 4 OCTOBER 1999 α-MSH INHIBITS NF-κB 563
Figure 2. Inhibition of NF-kB activation in
melanocytes and melanoma cells. Cumulative
scanning densitometry data for NF-κB p50/p65
expressed in: (a, b) A375-SM cutaneous melanoma
cells; (c) human ocular melanoma tumor cells; (d) human
ocular melanocytes; and (e) HBL cutaneous melanoma
cells. Data were analyzed under identical conditions
and then expressed relative to a maximum reading
taken for each experiment to allow combination of
data from all experiments. s, TNF-α (200 U per ml)
stimulation alone (a: n 5 9; c: n 5 4; d: n 5 3; e:
n 5 3); j, TNF-α (200 U per ml) 1 α-MSH (1 3
10–9 M) costimulation (a: n 5 9; b: 1 3 10–10 to 1 3
10–7 M α-MSH, n 5 3; c: n 5 4; d: n 5 3; e:
n 5 3); m, α-MSH (1 3 10–9 M) or IBMX (1 mM)
stimulation alone (a, c: n 5 4–15; d: n 5 6–8; e:
n 5 3); d, TNF-α (200 U per ml) 1 IBMX (1 mM)
(a, c: n 5 3; d: n 5 3). *p , 0.05; **p , 0.01;
***p , 0.005. Error bars: mean 6 SEM.
is believed to be a phosphorylated form of the native protein,
identified as the lower band.) Incubation with α-MSH at 10–9 M
α-MSH (the most effective inhibitory concentration on acute NF-
κB activation) was for 2, 8, or 16 h and was not found to alter the
relative level of IκB-α protein expression in comparison with
α-MSH-untreated cells (i.e., immunoreactive band size and
intensity). Although it is unlikely for protein expression to be
altered after a 2 h period, we investigated this time-point because
NF-κB activity was found to be inhibited maximally at this time
in all cell types investigated. A-375SM cells and HBL cells were
also incubated for 24 h with 10–10 M, 10–9 M, 10–8 M, and
10–7 M α-MSH (Fig 3). No changes in the relative level of IκB-α
protein expression were observed, however, when compared with
the corresponding untreated cell type.
DISCUSSION
α-MSH is a neuropeptide which occurs not only in the brain, but
also in distant tissues including skin and gut (Eberle, 1988; Catania
and Lipton, 1993; Lipton and Catania, 1997) and arises by pro-
opiomelanocortin processing. A long-standing interest exists in the
regulatory role of this peptide. When considering the wide tissue
distribution of α-MSH, however, several workers have suggested
alternative roles in controlling host reactions. In particular, the
control of fever, inflammation, and secretion of C-reactive protein
(see Lipton and Catania, 1997, for recent comprehensive review).
A number of in vivo studies demonstrate α-MSH to have potent
anti-inflammatory and anti-pyretic activities (Hiltz and Lipton,
1989; Hiltz et al 1991; Lipton et al, 1991; Martin et al, 1991;
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Figure 3. Lack of effect of a-MSH on IkB-a protein expression.
Western immunoblotting for IκB-α protein expression in A-375SM and
HBL cutaneous melanoma cells (immunoreactive product at 37 kDa). Cells
were stimulated with 10–9 M α-MSH for various times (2–16 h) and with
various concentrations of α-MSH (10–10 M to 10–7 M) for 24 h, as
indicated. Whole cell extracts were analyzed (10 µg of total protein
was loaded per gel track). Results shown are representative of three
repeat analyses.
Watanabe et al, 1993; Ceriani et al, 1994; Rajora et al, 1997), the
breadth of which have been compared with that of the adrenal
steroids (Lipton and Catania, 1997). Several studies show that the
anti-inflammatory action may arise by way of two distinct pathways:
(i) by a neural mechanism whereby α-MSH is released in the brain
and interacts with resident MC receptors, and acts on distal injury
sites by an efferent neural β2 adrenergic-dependent pathway, and
(ii) by local release of α-MSH at the site of injury acting on
cells by a paracrine/autocrine mechanism. A glucocorticoid-based-
dependent action is not thought to be involved. Rather, α-MSH
is thought to inhibit the production/action of proinflammatory
cytokines [e.g., TNF-α (Morandini et al, 1998), IL-1 (Weiss et al,
1991), IL-6 (Martin et al, 1991)] and also the production of anti-
inflammatory cytokines (e.g., IL-10; Bhardwaj et al, 1996).
α-MSH is now known to be produced locally by melanocytes
and keratinocytes (Kippenburger et al, 1995) and also by melanoma
tumors (Loir et al, 1997), as well as in skin (Farooqui et al,
1993). Production increases acutely following exposure of skin to
ultraviolet radiation (Schauer et al, 1994; Iyengar, 1995; Chakraborty
et al, 1996), together with the production of pro-inflammatory
cytokines (e.g., IL-1, TNF-α). Cytokine action can increase
expression of cell adhesion molecules (e.g., ICAM-1; Yohn et al,
1990) on target cells (in particular, melanocytes), and is an obligatory
step for interacting with T lymphocytes. We have previously
suggested that α-MSH may have a part in preventing melanocytes
from becoming premature targets for the immune system under
such circumstances. Indeed, recent work from our group documents
that α-MSH strongly opposes TNF-α-stimulated upregulation of
ICAM-1 expression in melanocytes in vitro (Hedley et al, 1998).
In considering melanoma biology, it is generally thought that
the level of cell surface adhesion molecule expression contributes
to the metastatic potential of the cell (Pandolfi et al, 1993). For
example, ICAM-1 is expressed at higher levels in metastatic vs.
primary melanoma (Natali et al, 1990). On the other hand, the
level of cell surface expression also relates to the ability of target
cells to bind to lymphocytes and macrophages at a primary tumor
site. ICAM-1, for example, possesses ligands on inflammatory cells
[LFA-1 (CD18/CD11a), Mac-1 (CD18/CD11b), CD43 (sialo-
glycoprotein)] which facilitate such a role. Whereas this has
previously been argued to assist cell detachment and separation
(Johnson, 1991), it may equally be argued to assist in the effective
removal of transforming or transformed cells. Either way, an
understanding of the regulatory pathway of ICAM-1 expression in
relation to tumor progression has a direct bearing on melanoma
biology. The antagonistic effects of α-MSH on inflammatory
reactions, in which expression of cell adhesion molecules are
implicated, may be of importance when considering that α-MSH
can be produced by melanoma tumor cells, raising the possibility
of autocrine/paracrine control.
The importance of α-MSH in the context of melanoma biology
in vivo has been reported many times previously. Studies have
shown that mouse B16 melanoma cells incubated with α-MSH
prior to injection in the mouse become far more metastatic in
comparison with untreated melanoma cells (Bennet et al, 1986).
Further support of these findings by our own group revealed a
positive correlation between the metastatic potential in vivo of the
B16 melanoma cell lines and the intracellular generation of cyclic
adenosine monophosphate (cAMP) in response to α-MSH or
forskolin (Hill et al, 1990).
More recently, we reported that α-MSH can strongly oppose
TNF-α-stimulated expression of ICAM-1 in vitro in several
melanoma cell types (Morandini et al, 1998). The cell signaling
mechanism by which α-MSH may exert such potent anti-inflam-
matory properties, however, is not known. The latter study showed
that a decrease in the mRNA transcript of ICAM-1 is detectable
prior to a decrease in ICAM-1 protein production (Morandini
et al, 1998). This suggested that α-MSH is likely to operate at an
early time-point in cell signaling, probably before the production
of the transcriptional message.
NF-κB is an inducible transcription factor which is present in
many cell types and has a central role in the cellular control of
inflammatory processes (Baeuerle and Henkel, 1994; Ghosh et al,
1998). Its own activity is regulated by several factors, but in
particular by pro-inflammatory cytokines. Activation is rapid, and
requires targeted proteolysis of IκB (the NF-κB inhibitor subunit).
This permits release of an active Rel dimer which is translocated
from the cytoplasm to the nucleus. Subsequent binding to a
consensus sequence present within given gene promoter regions in
turn controls the transcriptional expression of several genes
(Baeuerle and Henkel, 1994). Cell adhesion molecules including
ICAM-1 and interleukin receptors (e.g., IL-2 receptor) are some
of the genes reported to contain NF-κB consensus sequence motifs,
and expression of these molecules is largely thought to be under
the control of this transcription factor (Jahnke and Johnson, 1994;
Muller et al, 1995). Accordingly, this study investigated a possible
interaction between α-MSH and the pro-inflammatory cytokine
activation of NF-κB.
In two cutaneous melanoma cell lines, ocular melanoma cells
cultured from patient tumor material and human ocular melano-
cytes, we consistently observed no constitutive level of NF-κB
activity. Stimulation of cells with TNF-α acutely increased levels
of a DNA-binding protein, identified as an NF-κB complex with
a p50/p65 composition. Activity was maximal after 2 h incubation
for all of the cell types, with lower levels identified after 1 and 3 h.
Human ocular melanocytes differed slightly when compared with
the melanoma cells in terms of time taken for NF-κB activation.
Here, maximal levels were observed as soon as 1 h incubation,
with similar levels maintained after 2 h. For melanocytes and
melanoma cells a reduction in activity after 3 h was observed.
When cells were incubated with both α-MSH and TNF-α,
significant reductions in the NF-κB DNA binding activity were
observed. The α-MSH concentration chosen (1 3 10–9 M) for
these studies was the most effective at inhibiting NF-κB activity
in response to TNF-α in A375-SM cells after a 2 h stimulatory
period. This inhibitory concentration was also found to be most
effective for attenuation of ICAM-1 expression in melanocytes and
melanoma cells based on previous work by our group (Hedley
et al, 1998; Morandini et al, 1998). The inhibitory action of α-MSH
was observed to differ between cell types. After 1 h, this varied
from 81% inhibition for HBL cells to 37% for ocular melanoma
tumor cells. Further work using NF-κB reporter constructs would
support evidence that α-MSH decreases transcriptional gene expres-
sion (of inflammatory molecules, in particular). This study using
electrophoretic mobility shift assay and supershift analysis, however,
provides firm evidence that the NF-κB fraction identified is a p50/
p65 heterodimer and will therefore have transcriptional activating
potential. It is also possible that other transcription factors involved
in controlling the expression of molecules with a role in inflam-
matory and immune responses may be responsive to α-MSH [e.g.,
AP-1 (c-jun/fos), the STAT family and steroid receptors].
Regulation of IκB protein expression was measured in response
to α-MSH as a potential mechanism for regulating NF-κB activity.
IκB was detected in total cell extracts in unstimulated A-375SM
and HBL cells. It was found that no changes in expression arose as
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detected by Western immunoblotting when cells were incubated
for time-points ranging from 2 h to 24 h, using the most effective
α-MSH concentration demonstrated to inhibit acute NF-κB activa-
tion (10–9 M). Further, at 24 h incubation, varying the concentration
of α-MSH (10–11–10–8 M) did not alter the relative level of IκB
protein expression in either cell type.
The autocrine production of α-MSH by the cells used in this
study has previously been reported on, and therefore it is possible
that functional interference might arise in this inhibitory study.
The HBL cell line is known to produce a detectable amount of
α-MSH secreted into cell culture medium as measured immuno-
chemically, and detection is also reported for cultured human
melanoma cells (Loir et al, 1997). Whereas immunodetection of
α-MSH may potentially suggest a functional autocrine role for this
peptide, there is as yet no direct evidence. Ideally, use of a specific
MC-1 receptor antagonist (or α-MSH antagonist) would provide
a good tool for investigation. With the exception of the naturally
occurring agouti and agouti-related proteins (for which extra MC-1
receptor mediated signaling are frequently reported), however, no
such antagonists as yet exist. Thus, it is possible that α-MSH might
be contributing to NF-κB modulation in the current experiments.
We observed that NF-κB activity was inhibited reproducibly for
all cell types using nanomolar concentrations of α-MSH, thus we
may infer that any autocrine α-MSH produced under these
experimental conditions must be of a subnanomolar level. Autocrine
production of α-MSH and regulation of NF-κB is a very real
possibility, but it is difficult to confirm or refute this possibility
without a functional antagonist to α-MSH or its receptor.
Five MC receptor subtypes have been cloned to date (MC-1R–
MC-5R) with MC-1R reported to be the subtype expressed
exclusively on the surface of melanocytes and melanoma cells
(Mountjoy et al, 1992). The MSH receptor status for the cells used
in this study have previously been investigated (Ghanem et al,
1988; Goodall et al, 1994; Baumann et al, 1997). The HBL cell
line typically expresses 2000–3000 MSH binding sites per cell
(Ghanem et al, 1988), in contrast with the A-375SM cell line
where 600 sites per cell are usual (Baumann et al, 1997). It is of
note that a strong positive correlation exists between the proportion
by which NF-κB was inhibited at a given α-MSH concentration
in these two cell types and the above reported receptor numbers.
Ocular melanocytes and melanoma cells are also known to express
the MSH receptor and in addition respond functionally to α-MSH
stimulation (e.g., with changes in melanosome size) (Goodall et al,
1994). The binding of α-MSH to its receptor operates via a
G-protein coupled pathway, activating adenylate cyclase (which
transiently increases cAMP) and subsequent activation of the protein
kinase A pathway. We report on confirmatory data in this study
where the inhibitory activity of α-MSH was mimicked to a
very similar extent by the use of IBMX (an inhibitor of the
phosphodiesterase enzyme responsible for the removal of cAMP,
hence IBMX serves to elevate cAMP). Therefore, data may also
suggest a fundamental interaction exists between cAMP elevation
and NF-κB inhibition in melanocytes and melanoma cells, at early
time-points in cell signaling. This has previously been reported for
human monocytic cells (Ollivier et al, 1996).
The finding that α-MSH is able to attenuate NF-κB transcription
factor activity in vitro has wide implications in understanding its
role as an anti-inflammatory/immunomodulatory peptide. NF-κB
is known to control the transcription of many types of genes, and
as a consequence resulting effects may alter the expression and
function of a number of proteins. Good evidence exists for ICAM-1
being one such candidate protein; however, other eligible proteins
include additional cell adhesion molecules, cytokines, cytokine
receptors, and acute phase response proteins (Ghosh et al, 1998).
When considered in general terms, the majority of cellular responses
arising via the NF-κB transcription factor involve those concerned
with inflammation, cell migration and repair, and the activation of
immune cells. This study provides supporting data for studies which
report that α-MSH decreases fever, inflammation, or cytokine-
stimulated ICAM-1 cell expression, all of which would be consistent
with a suppression of NF-κB activity. This has been reported
recently for α-MSH in inflammatory cells (Manna and Aggarwal,
1998). The authors of this study, however, found that NF-κB
activity was maximally inhibited after a 24 h preincubation period
with α-MSH, with little or no inhibition at incubation time-points
below 12 h. The cutaneous cell types used in this study contrast
markedly in this respect in that very acute α-MSH treatment (15 min
preincubation prior to proinflammatory cytokine administration)
demonstrates strong transcription factor inhibition. It is also of
interest to note that other studies report that anti-inflammatory
drugs such as the salicylates and the corticosteroid dexamethasone
inhibit NF-κB activation in cultured cells (Ray and Prefontaine,
1991; Kopp and Ghosh, 1994; Auphan et al, 1995; Scheinman et al,
1995) and that aspirin and salicylate were more recently shown to
inhibit IκB kinase-β (Yin et al, 1998).
These findings also extend to the role of immune-inflammatory
cytokines which have the potential to reduce cellular proliferation
and melanogenesis in melanocytes and melanoma cells. TNF-α,
TNF-β, IL-1α, IL-1β, and IL-6 have previously been reported to
inhibit proliferation and tyrosinase activity [whereas the cytokines
IL-2, IL-3, and IL-4 were found not to have this effect (Swope
et al, 1991; Krasagakis et al, 1995)]. This certainly raises the
possibility that the processes of proliferation and/or melanogenesis
may be inhibited (or under a degree of control) by NF-κB.
Whereas evidence in support of this for melanocytes and melanoma
cells is circumstantial, a number of reports suggest NF-κB to have
regulatory control on proliferation and programmed cell death in
several other cell types. The precise role of NF-κB appears to be
highly dependent on cell type, but a general role in preventing
apoptosis is emerging. It is of interest to note that the use of
curcumin, a compound with strong antiproliferative effects in many
tumor cell types, strongly reduces NF-κB activity in cancer cells
(Mehta et al, 1997). As many of the cytokines which have
regulatory control on melanocyte/melanoma cell proliferation and
melanogenesis also activate NF-κB, it is possible that NF-κB
involvement is necessary. It would be of interest to investigate
such a role (e.g., by inhibiting NF-κB activation by use of an
overexpressing IκB transfection vector) and studying the behavior
of the above cytokines on proliferation and melanogenesis.
In conclusion, our data support α-MSH acting via a local
paracrine/autocrine mechanism to control the expression of mole-
cules involved in inflammation by attenuation of the pro-inflam-
matory cytokine pathway. We report, to the best of our knowledge,
for the first time, that this mechanism can operate via acute
regulation on the transcriptional activator NF-κB in two cutaneous
melanoma cell lines, and in ocular melanocytes and melanoma
cells. α-MSH, however, was not found to have any effect on the
relative level of IκB-α protein expression. Data are discussed in
the light of an anti-inflammatory role for α-MSH with respect to
melanocyte and melanoma biology. Thus, α-MSH may assist
melanoma cells to resist the actions of local proinflammatory
cytokine release, reducing the chance of tumor cell interaction
with infiltrating T lymphocytes. This may assist successful metastasis.
A similar mechanism may prevent melanocytes also becoming
immune cell targets following extreme local damage (e.g., by
ultraviolet irradiation).
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